Pipeline

At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.

Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.

DISEASE STATES

ASTHMA
Phase 3

Long-acting IL-5 antagonist (depemokimab)

SWIFT 1: Placebo-Controlled Efficacy and Safety Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype

Go to ResourceOpen link icon

SWIFT 2: A Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype    

Go to ResourceOpen link icon

NIMBLE: A Study of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Go to ResourceOpen link icon

An Open-Label Extension Study of Depemokimab in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Go to ResourceOpen link icon
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Phase 3

IL-5 antagonist (mepolizumab)

MATINEE: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Go to ResourceOpen link icon
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase 1

Prospective Observational Study

Longitudinal Study for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

Go to ResourceOpen link icon
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase 2

Prospective Observational Study

Longitudinal Study for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

Go to ResourceOpen link icon
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase 3

Prospective Observational Study

‌Longitudinal Study for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

Go to ResourceOpen link icon

Long-acting IL-5 antagonist (depemokimab)

OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA

Go to ResourceOpen link icon
HYPEREOSINOPHILIC SYNDROME
Phase 3

IL-5 antagonist

SPHERE: Study in Pediatrics With HypEREosinophilic Syndrome

Go to ResourceOpen link icon

Long-acting IL-5 antagonist (depemokimab)

DESTINY: Depemokimab in Participants With HES, Efficacy, and Safety Trial

Go to ResourceOpen link icon
CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Phase 3

Long-acting IL-5 antagonist (depemokimab)

ANCHOR-1: Efficacy and Safety of Depemokimab in Participants with CRSwNP

Go to ResourceOpen link icon

ANCHOR-2: Efficacy and Safety of Depemokimab in Participants with CRSwNP

Go to ResourceOpen link icon
PHARMACOKINETIC STUDY
Phase 3

Long-acting IL-5 antagonist (depemokimab)

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Go to ResourceOpen link icon
REFRACTORY CHRONIC COUGH
Phase 3

P2X3 Antagonist (camlipixant [BLU-5937])

CALM-1: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough 

Go to ResourceOpen link icon

P2X3 Antagonist (camlipixant [BLU-5937])

CALM-2: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough 

Go to ResourceOpen link icon

0 results - Use filter to search Pipeline